Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Jul 31, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called XJ-MK-002, which uses special cells from umbilical cord blood to help people who have low platelet counts caused by cancer treatments like chemotherapy. Platelets are important because they help your blood clot, so having too few can increase the risk of bleeding. This early-stage study aims to see if this cell therapy is safe and well-tolerated in adults aged 18 to 75 who have low platelets due to their cancer treatment.

If you join the study, you will receive just one injection of these cells at one of three dose levels, depending on the group you’re placed in. After the treatment, you’ll be closely monitored for about a month to watch for any side effects. To be eligible, participants need to have a confirmed cancer diagnosis, a low but stable platelet count, and be generally healthy enough to participate without severe bleeding or other serious medical issues. The trial is not yet recruiting, but if you’re interested, your doctor can help determine if this study might be appropriate for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects aged 18 to 75 years (inclusive) at the time of signing the informed consent, regardless of gender.
• • 2. Histologically and/or cytologically confirmed diagnosis of a malignant tumor, with thrombocytopenia due to anti-tumor treatments (e.g., chemotherapy, immunotherapy, targeted therapy, and radiotherapy), 50×10⁹/L≤platelet count (PLT) is ≤100×10⁹/L, confirmed by blood tests (with reconfirmation on the day prior to infusion) and with no bleeding
• • 3. No transfusion of platelets or blood products containing platelet components within 72 hours prior to investigational product administration.
• • 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
• • 5. Estimated life expectancy of more than 3 months.
• • 6. Female subjects of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception methods in accordance with ICH M3 (R2) guidelines during the trial and for 6 months after administration. Male subjects must also agree not to donate sperm during this period. WOCBP must have a negative pregnancy test result within 7 days prior to enrollment.
• Exclusion Criteria:
• • 1. History of platelet transfusion refractoriness.
• • 2. History of severe allergic reactions related to blood transfusion.
• • 3. History of bleeding disorders or thrombocytopenia caused by conditions other than CTIT.
• • 4. Splenomegaly or hypersplenism.
• • 5. Use of thrombopoietin-stimulating drugs within 7 days prior to receiving the investigational product, including recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11), romiplostim, eltrombopag, hetrombopag, leucogen tablets, aminopeptidase tablets, and caffeic acid tablets.
• • 6. Subjects with existing severe bleeding (e.g., cerebral hemorrhage, severe gastrointestinal bleeding, or severe hemoptysis).
• • 7. Subjects with hemophilia or coagulation disorders.
• • 8. History of thromboembolic diseases (deep vein thrombosis, arterial thrombosis) within 6 months before screening, or patients with catheter-related thrombosis within 1 month before screening.
• • 9. History of cardiac diseases within 3 months before screening, or a history of severe cardiovascular diseases (e.g., congestive heart failure (NYHA Class 3/4), known arrhythmias that increase the risk of thromboembolic events (e.g., atrial fibrillation, atrial flutter, unstable angina), coronary stent placement, angioplasty, or coronary artery bypass grafting).
• • 10. Major organ surgery (excluding needle biopsy) or severe trauma within 4 weeks before administration of the investigational product or anticipated major surgery during the trial.
• • 11. Use of anticoagulant drugs within 7 days before screening, including vitamin K antagonists, low molecular weight heparin (except for minimal heparin use for catheter locking), factor Xa inhibitors (e.g., rivaroxaban), thrombin inhibitors, and/or antiplatelet therapy (e.g., aspirin).
• • 12. Coagulation function abnormalities: activated partial thromboplastin time (APTT) \>1.5× upper limit of normal (ULN); international normalized ratio (INR) \>1.5×ULN.
• • 13. Liver and kidney function abnormalities: liver function (for non-liver cancer patients or those without liver metastasis): total bilirubin (TBIL) \>2.5×ULN, alanine aminotransferase (ALT) \>2.5×ULN, aspartate aminotransferase (AST) \>2.5×ULN; renal function: creatinine clearance (Ccr) \<50 mL/min, or serum creatinine (Cr) \>1.5×ULN.
• • 14. Complete blood count abnormalities: Absolute neutrophils count \<1.0×109/L, hemoglobin \<80g/L (use of erythropoietin infusion therapy according to clinical standards is allowed during screening).
• • 15. Positive serology tests during screening: positive anti-HIV antibody or anti-treponema pallidum specific antibody test; or positive hepatitis C antibody with HCV RNA copy number above the upper limit of normal, positive hepatitis B surface antigen, or history of hepatitis B infection; or positive hepatitis B core antibody with HBV-DNA ≥2000 IU/mL within the last 3 months before screening.
• • 16. Uncontrolled severe chronic or active infection requiring intravenous antibiotic treatment before administration.
• • 17. Subjects with known allergies to the investigational product, its active ingredients, or any of its excipients.
• • 18. Use of any investigational product with a similar mechanism of action within 4 weeks prior to administration of the investigational product, or current participation in another clinical trial (except for observational, non-interventional clinical trials, or the follow-up period of an interventional clinical trial).
• • 19. History of hematopoietic stem cell transplantation with acute graft-versus-host disease requiring therapeutic intervention.
• • 20. Pregnant or lactating female subjects.
• • 21. Any other medical condition that, in the investigator's judgment, precludes participation in this study or completion of follow-up observations.